ABC | Volume 112, Nº4, April 2019

Original Article Yang Li Risk factors for PTSMA complications Arq Bras Cardiol. 2019; 112(4):432-438 This is an open-access article distributed under the terms of the Creative Commons Attribution License 15. Gomes OM, Coelho AA, Osterne EC, Abrantes RD. Coronary morphology and conduction system disturbance induced by therapeutic embolization of the coronary septal artery. Heart Surg Forum. 2010;13(1):E45-8. 16. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D , Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119(2):163-7. 17. El-Jack SS, Nasif M , Blake JW , Dixon SR, Grines CL, O’Neill WW . Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20(1):73-6. 18. van der Lee C, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van DomburgRT , et al.Usefulnessof clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008;101(9):1315-20. 19. Veselka J,ZemánekD, TomasovP , DuchonováR, LinhartováK. Alcoholseptal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels. 2009;24(1):27-31. 20. Gersh BJ, Maron BJ, Bonow RO , Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24): 2761-96. 21. Qiao SB, Yuan JS. How to improve the safety of percutaneous transluminal septal myocardial ablation. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(3):193-5. 438